(Total Views: 516)
Posted On: 10/02/2019 6:36:57 AM
Post# of 153888
From Seeking Alpha today: FDA OKs CytoDyn's mid-stage leronlimab trial
Oct. 2, 2019 6:29 AM ET|About: CytoDyn Inc. (CYDY)|By: Mamta Mayani, SA News Editor
CytoDyn (OTCQB:CYDY) announces FDA clearance to initiate enrollment in its Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.
60 patients will be enrolled in the trial.
Oct. 2, 2019 6:29 AM ET|About: CytoDyn Inc. (CYDY)|By: Mamta Mayani, SA News Editor
CytoDyn (OTCQB:CYDY) announces FDA clearance to initiate enrollment in its Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
The trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.
60 patients will be enrolled in the trial.
(1)
(0)
